Cargando…
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...
Autores principales: | Vietri, Lucia, Cameli, Paolo, Perruzza, Marco, Cekorja, Behar, Bergantini, Laura, d’Alessandro, Miriana, Refini, Rosa Metella, Pieroni, Maria, Fossi, Antonella, Bennett, David, Spalletti, Marco, Mazzei, Maria Antonietta, Sestini, Piersante, Rottoli, Paola, Bargagli, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029533/ https://www.ncbi.nlm.nih.gov/pubmed/32066332 http://dx.doi.org/10.1177/1753466620906326 |
Ejemplares similares
-
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020) -
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021) -
Adaptive immune system in pulmonary sarcoidosis—Comparison of peripheral and alveolar biomarkers
por: d’Alessandro, Miriana, et al.
Publicado: (2021) -
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
por: Cameli, Paolo, et al.
Publicado: (2020) -
The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis
por: Refini, Rosa Metella, et al.
Publicado: (2020)